Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 2/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306515 | 1.00 | ENPP3 (0.36) | ENPP3ENPP1AXLPRKCICDC7 | |
| SCHEMBL15280118 | 0.81 | CCR1 (0.38) | — | |
| SCHEMBL29660486 | 0.80 | — | — | |
| SCHEMBL1002153 | 0.80 | — | — | |
| SCHEMBL29660466 | 0.80 | MGAM (0.34) | PRKCI | |
| SCHEMBL2794776 | 0.80 | — | — | |
| SCHEMBL794853 | 0.80 | MGAM (0.34) | PRKCI | |
| SCHEMBL12594299 | 0.79 | — | — | |
| SCHEMBL15155025 | 0.79 | MGAM (0.34) | PRKCI | |
| SCHEMBL4285909 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038910-A1 | CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITOR AND METHODS FOR ITS PREPARATION | ACLARIS THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| CN-119241542-A | Solid forms of FGFR inhibitors and methods of making the same | 因赛特公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119241540-A | Solid forms of FGFR inhibitors and methods of making the same | 因赛特公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119241541-A | Solid forms of FGFR inhibitors and methods of making the same | 因赛特公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240425506-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | INCYTE CORPORATION | 2024-12-26 | — | — | US | disclosed |
| CN-119119039-A | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | 阿克拉瑞斯治疗股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-111566095-B | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | 阿克拉瑞斯治疗股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-112867716-B | Solid forms of FGFR inhibitors and methods of making the same | 因赛特公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4309737-A2 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | Incyte Corporation (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| CN-113200983-B | Compound with pyrrolopyridine structure, preparation method and medical application | 中国药科大学 | 2023-01-03 | — | — | CN | disclosed |
| CN-115385911-A | Compound with dipyrrolopyridine structure, preparation method and medical application | 南京康屹生物医药中心(有限合伙) | 2022-11-25 | — | — | CN | disclosed |
| EP-4069695-A1 | DERIVATIVES OF AN FGFR INHIBITOR | Incyte Corporation (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11466004-B2 | Solid forms of an FGFR inhibitor and processes for preparing the same | INCYTE CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| CN-115151539-A | Derivatives of FGFR inhibitors | 因赛特公司 | 2022-10-04 | — | — | CN | disclosed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11407750-B2 | Derivatives of an FGFR inhibitor | INCYTE CORPORATION (US) | 2022-08-09 | — | — | US | disclosed |
| CN-114478528-A | Aroyl-substituted tricyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022051568-A1 | SUBSTITUTED 4-PIPERIDINYL-PYRROLO[2,3-B]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| CN-111518096-B | Janus kinase JAK family inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | ENPP3 2817/4885ENPP1 3333/4885AXL 1367/4885 |
| US-20240425506-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | FGFR1, FGFR2, FGFR3 | ENPP3 3507/4885ENPP1 3026/4885AXL 15/4885 |
| US-11407750-B2 | Derivatives of an FGFR inhibitor | FGFR1, FGFR2, FGFR4 | ENPP3 4471/4885ENPP1 4451/4885AXL 77/4885 |
| US-11466004-B2 | Solid forms of an FGFR inhibitor and processes for preparing the same | FGFR1, FGFR2, FGFR3 | ENPP3 3507/4885ENPP1 3026/4885AXL 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.